Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease
Recruiting · NCT06982079 · Interventional (participants receive a specific treatment) · Lead sponsor: Ain Shams University
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The goal of this clinical trial is to evaluate whether dapagliflozin can reduce the risk of worsening kidney function or death from cardiovascular or renal causes in adults with advanced chronic kidney disease (CKD), with or without type 2 diabetes. The main questions it aims to answer are: 1. Does dapagliflozin reduce the rate of decline in kidney function or progression to end-stage kidney disease in adults with advanced CKD? 2. Does dapagliflozin reduce the risk of death from cardiovascular or renal causes in patients with advanced CKD? Researchers will compare dapagliflozin to a placebo to see if dapagliflozin improves kidney and cardiovascular outcomes in this high-risk population.
Who can take part
Inclusion criteria
- Adult patients aged eighteen or older.
- Patients with advanced chronic kidney disease (i.e., eGFR \< 20 mL/min/1.73m2)not on dialysis
Exclusion criteria
- Autosomal dominant polycystic kidney disease (ADPKD).
- Type 1 diabetes mellitus
- Patients on SGLT2 inhibitors.
- History of ketoacidosis in the last 3 months.
- Known hypersensitivity to SGLT2 inhibitors.
- Known hepatic impairment.
- Pregnant or breastfeeding females.
Where it is running
1 location listed.
- Ain Shams University Hospitals - Cairo, Egypt